Payment overview · 2025
General Payments
$181.14
10 reported records · 8 companies
Healthcare provider profile · identity verified
Edith K Mcguire, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FARMINGTON, NM · NPI 1376105817
Verified facts
What the public records show
CMS Open Payments records show Edith K Mcguire, CNP received $181.14 in general payments during 2025 across 10 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.42 | 19.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.65 | 18.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.07 | 16.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.25 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.63 | 10.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.97 | 9.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.86 | 8.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.29 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.14 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $32.65 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 150 |
| Lisinopril | Lisinopril | 363 | 126 |
| Gabapentin | Gabapentin | 336 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 76 |
| Metformin Hcl | Metformin Hcl | 233 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 189 | 42 |
| Metformin Hcl Er | Metformin Hcl | 180 | 61 |
| Omeprazole | Omeprazole | 166 | 53 |
| Losartan Potassium | Losartan Potassium | 154 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 47 |
| Furosemide | Furosemide | 150 | 48 |
| Glipizide Er | Glipizide | 141 | 48 |
| Ibuprofen | Ibuprofen | 140 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 37 |
| Glipizide | Glipizide | 95 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 29 |
| Montelukast Sodium | Montelukast Sodium | 84 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 28 |
| Trazodone Hcl | Trazodone Hcl | 77 | 28 |
| Atrovent Hfa | Ipratropium Bromide | 74 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 23 |
| Meloxicam | Meloxicam | 61 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 26 |
| Carvedilol | Carvedilol | 59 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Januvia | Sitagliptin Phosphate | 54 | 20 |
| Ozempic | Semaglutide | 52 | 13 |
| Tradjenta | Linagliptin | 51 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 14 |
| Famotidine | Famotidine | 47 | 19 |
| Jardiance | Empagliflozin | 47 | 14 |
| Simvastatin | Simvastatin | 47 | 17 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 15 |
| Sertraline Hcl | Sertraline Hcl | 38 | 15 |
| Allopurinol | Allopurinol | 36 | 16 |
| Eliquis | Apixaban | 36 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 15 |
| Memantine Hcl | Memantine Hcl | 35 | 13 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Naproxen | Naproxen | 30 | 13 |
| Techlite Pen Needle | Pen Needle, Diabetic | 30 | 19 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Prednisone | Prednisone | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Estradiol | Estradiol | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.14 · 10 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, BEXSERO, CAPLYTA, COBENFY, Cologuard Collection Kit, MAVYRET, MINIMED 780G, PENBRAYA, PREVNAR 20, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error